Cipla Ltd vs Jenburkt Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 10, 2026

Key Highlights

The Latest Trading Price of Cipla Ltd is ₹ 1380 as of 10 Jun 13:38 . The P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 25.5 on March 2026 . This represents a CAGR of -1.13% over 6 yearsThe P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 98795 crore on March 2026 . This represents a CAGR of 7.02% over 6 yearsThe Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of Cipla Ltd for the Mar '26 is ₹ 6689 crore as compare to the Dec '25 revenue of ₹ 7280 crore. This represent the decline of -8.12% The revenue of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Cipla Ltd for the Mar '26 is ₹ 1103 crore as compare to the Dec '25 ebitda of ₹ 1185 crore. This represent the decline of -6.95% The ebitda of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 550.11 crore over 8 quarters. This represents a CAGR of -31.61% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 29.87 % on March 2026 . This represents a CAGR of 10.58% over 6 yearsThe Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 years .

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 48 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

FAQs for the comparison of Cipla Ltd and Jenburkt Pharmaceuticals Ltd

Which company has a larger market capitalization, Cipla Ltd or Jenburkt Pharmaceuticals Ltd?

Market cap of Cipla Ltd is 111,220 Cr while Market cap of Jenburkt Pharmaceuticals Ltd is 513 Cr

What are the key factors driving the stock performance of Cipla Ltd and Jenburkt Pharmaceuticals Ltd?

The stock performance of Cipla Ltd and Jenburkt Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Jenburkt Pharmaceuticals Ltd?

As of June 10, 2026, the Cipla Ltd stock price is INR ₹1376.75. On the other hand, Jenburkt Pharmaceuticals Ltd stock price is INR ₹1163.2.

How do dividend payouts of Cipla Ltd and Jenburkt Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cipla Ltd and Jenburkt Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.